Atara Biotherapeutics Receives Nasdaq Notice Regarding Minimum Market Value Deficiency

On April 30, 2026, Atara Biotherapeutics, Inc. received a deficiency notice from the Nasdaq Listing Qualifications Department indicating that the company no longer meets the minimum Market Value of Listed Securities (MVLS) requirement of $50 million for continued listing on the Nasdaq Global Select Market. This determination was based on the company's market value over the previous 30 consecutive business days. Under Nasdaq Listing Rules, Atara has been granted a 180-calendar day grace period, expiring on October 27, 2026, to regain compliance. To resolve the deficiency, the company's MVLS must close at $50 million or higher for at least 10 consecutive business days before the deadline. The notice does not result in immediate delisting, and the common stock continues to trade under the symbol 'ATRA'. Atara is currently monitoring its market value and considering options to regain compliance, which may include transferring its listing to The Nasdaq Capital Market. If compliance is not achieved by the deadline, the company may face delisting, subject to an appeal process.